Literature DB >> 10424245

Auto-antibodies in hepatitis C.

D Zauli1, F Cassani, F B Bianchi.   

Abstract

Hepatitis C virus (HCV) has been implicated in the development of a variety of autoimmune phenomena, some of which are well documented and include a panel of auto-antibodies shared with autoimmune hepatitis (AIH). Anti-nuclear (ANA) and smooth muscle (SMA) antibodies (markers of AIH type 1 [AIH-1]), have been demonstrated in 9-38% and 5-91% of cases respectively, whereas anti-liver/kidney microsomal type 1 (anti-LKM-1) and anti-liver cytosol type 1 antibodies (anti-LC1) (markers of AIH type 2 [AIH-2]), are definitely rarer, especially in adults. The presence of these auto-reactivities in chronic hepatitis C generates clinical overlaps and dilemmas in the correct classification and treatment of such patients. The immunopathological characterization of the auto-antibodies, anti-nuclear and smooth muscle antibodies in particular, combined with internationally defined criteria for the diagnosis of AIH is helpful in this clinical process. Thyroid auto-antibodies and cryoprecitable rheumatoid factors are also commonly detected in hepatitis C, while the occurrence of other auto-antibodies still awaits confirmation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10424245     DOI: 10.1016/S0753-3322(99)80094-8

Source DB:  PubMed          Journal:  Biomed Pharmacother        ISSN: 0753-3322            Impact factor:   6.529


  5 in total

1.  Immune response to extracellular matrix collagen in chronic hepatitis C-induced liver fibrosis.

Authors:  Brian B Borg; Anil Seetharam; Vijay Subramanian; Haseeb Ilias Basha; Mauricio Lisker-Melman; Kevin Korenblat; Christopher D Anderson; Surendra Shenoy; William C Chapman; Jeffrey S Crippin; Thalachallour Mohanakumar
Journal:  Liver Transpl       Date:  2011-07       Impact factor: 5.799

2.  The presence of non-organ-specific autoantibodies is associated with a negative response to combination therapy with interferon and ribavirin for chronic hepatitis C.

Authors:  Hermann E Wasmuth; Christian Stolte; Andreas Geier; Christoph G Dietrich; Carsten Gartung; Johann Lorenzen; Siegfried Matern; Frank Lammert
Journal:  BMC Infect Dis       Date:  2004-02-13       Impact factor: 3.090

3.  Low prevalence of liver-kidney microsomal autoantibodies of type 1 (LKM1) in hepatitis C seropositive subjects on Crete, Greece.

Authors:  D Drygiannakis; C Lionis; I Drygiannakis; G Pappas; E Kouroumalis
Journal:  BMC Gastroenterol       Date:  2001-06-11       Impact factor: 3.067

4.  Anti-rods/rings autoantibody seropositivity does not affect response to telaprevir treatment for chronic hepatitis C infection.

Authors:  S John Calise; Nicola Bizzaro; Thuy Nguyen; Danila Bassetti; Brunetta Porcelli; Paolo Almi; Giuseppina Barberio; Giampaola Pesce; Minoru Satoh; Edward K L Chan
Journal:  Auto Immun Highlights       Date:  2016-11-14

5.  Clinical associations and potential novel antigenic targets of autoantibodies directed against rods and rings in chronic hepatitis C infection.

Authors:  Laura M Stinton; Robert P Myers; Carla S Coffin; Marvin J Fritzler
Journal:  BMC Gastroenterol       Date:  2013-03-19       Impact factor: 3.067

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.